Bacil Pharma board approves Rights Issue of up to Rs 50 Crores

Corporate Actions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹38.36

prior close

₹39.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-1.0% vs market

Pharmaceuticals peers, median of 167sector+0.4%+0.0% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.9

15m

-1.9

30m

-2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+1.4-1.0+0.4+0.0

Next day

-2.2+1.5-3.7+0.8-3.0

-2.2+0.5-2.7+0.5-2.7

-3.9+1.1-5.0+0.6-4.5

-3.8+0.7-4.5+0.5-4.3

-4.8-0.4-4.4-0.7-4.2

-14.3+0.5-14.8+0.3-14.6

15d

-43.0+0.1-43.1-1.8-41.3

-58.1+3.5-61.6-0.6-57.5

-51.6+5.8-57.4+2.4-54.0

-36.3+2.4-38.6-1.5-34.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma's board approved a Rights Issue of equity shares for up to Rs 50 Crores. Authorised share capital will rise by Rs 45 Crores to Rs 65 Crores, subject to shareholder approval. Two independent directors, Mr Dinesh Chander Notiyal and Ms Avani Savjibhai Godhaniya, resigned. Purva Sharegistry, Axis Bank and Acuite Ratings were appointed as registrar, banker and monitoring agency. Issue price, entitlement ratio and record date are yet to be decided.

Likely market impact

Rights issue may dilute existing shareholders if they do not subscribe. Key terms like price and ratio not yet announced, so watch for further updates.